Condition
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) clinical trials that are recruiting, at sites in 2 countries (most in United States (3), China (2)). 1 was first registered in the last 30 days. By phase: Phase 2 (2), Phase 2/3 (1), Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1New in 30 days
- 2Countries
Newest Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CR-002 study in adults with advanced solid tumors | Phase 1/2 | Austin, Texas and 2 other locations | Recruiting | Nov 2, 2026 |
| Anyouping® plus Enlituo® with platinum-based chemotherapy as first-line for advanced head and neck cancer | Phase 2/3 | Shanghai, Shanghai Municipality | Recruiting | Aug 28, 2026 |
| CCR2 PET Imaging for Head and Neck Squamous Cell Carcinoma | Phase 2 | St Louis, Missouri | Recruiting | Jun 22, 2026 |
| Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors | Phase 1 | Guangzhou, Guangdong | Recruiting | May 13, 2026 |
| Window of Opportunity to Preserve Laryngeal Function | Phase 2 | Pittsburgh, Pennsylvania | Recruiting | Feb 20, 2026 |
All recruiting trials (5)
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
Anyouping® plus Enlituo® with platinum-based chemotherapy as first-line for advanced head and neck cancer
This trial tests whether adding Anyouping® and Enlituo® to standard platinum-based chemo helps adults with advanced, recurring, or metastatic head and neck squamous cell carcinoma succeed more than standard chemo alone.
-
CCR2 PET Imaging for Head and Neck Squamous Cell Carcinoma
This trial tests whether Cu-64 DOTA-ECL1i PET/CT can reliably detect HNSCC in adults, including those with new locally advanced disease or suspected/confirmed recurrent/metastatic cancer.
-
Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors
This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.
-
Window of Opportunity to Preserve Laryngeal Function
This trial will try a short course of platinum chemotherapy plus paclitaxel and the immunotherapy toripalimab before surgery to see if adults with advanced laryngeal or hypopharyngeal squamous cell cancer can keep their voice box and still get good cancer control.
Related topics
Quick answers
How many Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) clinical trials are recruiting right now?
5, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (3 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 2/3: 1, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.